These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3718829)

  • 1. Evaluation of the biochemical effects of CHIP in normal and tumour-bearing C3H mice.
    Laverick M; Gordon M; Kind PR; Slavin BM; Nias AH
    Br J Cancer; 1986 Jun; 53(6):761-72. PubMed ID: 3718829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison in rodents of renal and intestinal toxicity of cisplatin and a new water-soluble antitumor platinum complex: N-methyl-iminodiacetato-diaminocyclohexane platinum (II).
    Newman RA; Khokhar AR; Sunderland BA; Travis EL; Bulger RE
    Toxicol Appl Pharmacol; 1986 Jul; 84(3):454-63. PubMed ID: 3726868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Criteria for the selection of second-generation platinum compounds.
    Shepherd R; Kusnierczyk H; Jones M; Harrap KR
    Br J Cancer; 1980 Nov; 42(5):668-76. PubMed ID: 7193043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of C3H mouse mammary tumour on the levels of serum and urine analytes in vivo.
    Kind PR; Gordon M; Laverick M; Nias AH; Slavin BM
    Br J Cancer; 1985 Oct; 52(4):607-12. PubMed ID: 4063136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical toxicology of platinum analogues in dogs.
    Lelieveld P; van der Vijgh WJ; van Velzen D
    Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1147-54. PubMed ID: 3308482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body hyperthermia as an adjuvant to treatment with platinum complexes with or without etanidazole in mice bearing the Lewis lung carcinoma or the FSaLL fibrosarcoma.
    Teicher BA; Herman TS; Menon K; Korbut TT
    Int J Hyperthermia; 1992; 8(6):783-94. PubMed ID: 1479204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
    Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative nephrotoxicity of cisplatin and new octahedral Pt(IV) complexes.
    Kim WK; Kwon YE
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):237-43. PubMed ID: 17089165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung tumour growth delay and normal tissue toxicity induced by three cytotoxic platinum drugs.
    van Rongen E; Kal HB; Kuijpers WC; van Berkel AH
    Strahlenther Onkol; 1992 May; 168(5):300-7. PubMed ID: 1598667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Toxic effect of cisplatin and certain platinum complexes of the 2d generation (CHIP, oxoplatina) on the gastrointestinal tract in rats].
    Filipová M; Srámek B; Kvĕtina J
    Bratisl Lek Listy; 1986 Jan; 85(1):49-53. PubMed ID: 3955396
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of the anticancer dehydrotarplatin on cytochrome P450 and antioxidant enzymes in male rat tissues.
    Nannelli A; Messina A; Marini S; Trasciatti S; Longo V; Gervasi PG
    Arch Toxicol; 2007 Jul; 81(7):479-87. PubMed ID: 17364183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nephrotoxicity and myelotoxicity of antineoplastic Pt(II) and Pt(IV) coordination compounds in rats].
    Horn U; Härtl A; Neuhaus G; Stöckel U; Schröer HP; Hoffmann H
    Arch Geschwulstforsch; 1989; 59(4):245-50. PubMed ID: 2802932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9).
    Schweitzer VG; Rarey KE; Dolan DF; Abrams G; Litterst CJ; Sheridan C
    Otolaryngol Head Neck Surg; 1986 Apr; 94(4):458-70. PubMed ID: 3086808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of adriamycin in mice bearing mammary adenocarcinoma 16/C.
    Simpson-Herren L; Noker PE
    Cell Prolif; 1991 May; 24(3):241-55. PubMed ID: 2039801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative nephrotoxicity of tetraplatin and cisplatin in rats.
    Rahman A; Roh JK; Preuss HG
    Nephron; 1993; 64(2):289-95. PubMed ID: 8321364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the structure and function of the kidney of rats chronically exposed to cadmium. I. Biochemical and histopathological studies.
    Brzóska MM; Kamiński M; Supernak-Bobko D; Zwierz K; Moniuszko-Jakoniuk J
    Arch Toxicol; 2003 Jun; 77(6):344-52. PubMed ID: 12799774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of side effects of platinum complexes (CDDP, CBDCA, CHIP) on rat bone marrow.
    Prajda N; Kralovánszky J; Gal F; Kiss F; Kerpel-Fronius S
    In Vivo; 1989; 3(4):267-70. PubMed ID: 2519864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents.
    McKeage MJ; Morgan SE; Boxall FE; Murrer BA; Hard GC; Harrap KR
    Br J Cancer; 1993 May; 67(5):996-1000. PubMed ID: 8494733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.